PPAR-γ agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage

Laboratory Investigation

Volumn 90, Issue 10, 2010, Pages 1517-1532

  Sandoval, Pilar ^a   Loureiro, Jess ^a   González Mateo, Guadalupe ^b   Pérez Lozano, Maria L ^a   Maldonado Rodríguez, Alejandra ^a   Sánchez Tomero, José A ^a   Mendoza, Lorea ^c   Santamaría, Beatriz ^d   Ortiz, Alberto ^d   Ruíz Ortega, Marta ^d   Selgas, Rafael ^b   Martín, Pilar ^e   Sánchez Madrid, Francisco ^a,e   Aguilera, Abelardo ^a   López Cabrera, Manuel ^a,e,f  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Pharmakine Ltd   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^f CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

Author keywords

advanced glycation end products; fibrosis; mesothelial to mesenchymal transition; peritoneal dialysis; regulatory T cells; rosiglitazone

Indexed keywords

INTERLEUKIN 10; PERITONEAL DIALYSIS FLUID; ROSIGLITAZONE; TRANSCRIPTION FACTOR FOXP3;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FUNCTIONAL DISEASE; INFLAMMATION; LEUKOCYTE; MESOTHELIUM CELL; MOUSE; NONHUMAN; PERITONEAL DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RETROPERITONEAL FIBROSIS;

ANIMALS; DIALYSIS SOLUTIONS; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; EPITHELIUM; FIBROSIS; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; IMMUNITY, CELLULAR; INFLAMMATION; MICE; PERITONEAL DIALYSIS; PERITONEUM; PPAR GAMMA; T-LYMPHOCYTES; THIAZOLIDINEDIONES;

EID: 77957272665     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2010.111     Document Type: Article

References (62)

1. Krediet RT. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999;55:341-356.
2. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure. Perit Dial Int 2000;20(Suppl 4):S22-S42.
3. Aroeira LS, Aguilera A, Sanchez-Tomero JA, et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007;18:2004-2013. (Pubitemid 47041064)
4. Yung S, Chan TM. Intrinsic cells: mesothelial cells - central players in regulating inflammation and resolution. Perit Dial Int 2009;29(Suppl 2): S21-S27.
5. Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002;13:470-479. (Pubitemid 34106290)
6. Mateijsen MA, Van der Wal AC, Hendriks PM, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999;19:517-525.
7. Plum J, Hermann S, Fusshöller A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl 2001;78:S42-S47. (Pubitemid 32144068)
8. Selgas R, Fernández-Reyes MJ, Bosque E, et al. Functional longevity of the human peritoneum: how long is continuous peritoneal dialysis possible? Results of a prospective medium long-term study. Am J Kidney Dis 1994;23:64-73. (Pubitemid 24021750)
9. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003;23:530-541. (Pubitemid 37527296)
10. Yáñez-Mo M, Lara-Pezzi E, Selgas R, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413. (Pubitemid 36159357)
11. Yang AH, Chen JY, Lin JK. Myofibroblastic conversion of mesothelial cells. Kidney Int 2003;63:1530-1539.
12. Jiménez-Heffernan JA, Aguilera A, Aroeira LS, et al. Immunohistochemical characterization of fibroblast subpopulations in normal peritoneal tissue and in peritoneal dialysis-induced fibrosis. Virchows Arch 2004;444:247-256. (Pubitemid 38446437)
13. Aguilera A, Yáñez-Mo M, Selgas R, et al. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs 2005;6:262-268. (Pubitemid 40424734)
14. Aroeira LS, Aguilera A, Selgas R, et al. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. Am J Kidney Dis 2005;46:938-948. (Pubitemid 41505470)
15. Aroeira LS, Lara-Pezzi E, Loureiro J, et al. Cyclooxygenase-2 mediates dialysate-induced alterations of the peritoneal membrane. J Am Soc Nephrol 2009;20:582-592.
16. Del Peso G, Jiménez-Heffernan JA, Bajo MA, et al. Epithelial-tomesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int Suppl 2008;108:S26-S33. (Pubitemid 351466514)
17. Rosenberg ME. Peritoneal dialysis: diabetes of the peritoneal cavity. J Lab Clin Med 1999;134:103-104.
18. Goh SY, Cooper ME. Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008;93:1143-1152.
19. Rosen ED, Spiegelman BM. PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276: 37731-37734. (Pubitemid 37384014)
20. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008;454:470-477. (Pubitemid 50280209)
21. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-1118. (Pubitemid 39167514)
22. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferatoractivated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82. (Pubitemid 28079218)
23. Castrillo A, Tontonoz P. Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 2004;20:455-480. (Pubitemid 39488646)
24. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, et al. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 2000;164:1364-1371. (Pubitemid 30067250)
25. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-759.
26. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol 2007;178:2940-2949. (Pubitemid 46333173)
27. Wohlfert EA, Nichols FC, Nevius E, et al. Peroxisome proliferatoractivated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 2007;178:4129-4135. (Pubitemid 46492362)
28. Li Y, Wen X, Spataro BC, et al. Hepatocyte growth factor is a downstream effector that mediates the antifibrotic action of peroxisome proliferator-activated receptor-gamma agonists. J Am Soc Nephrol 2006;17:54-65.
29. Kawai T, Masaki T, Doi S, et al. PPAR-g agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-b. Lab Invest 2009;89:47-58.
30. Ko GJ, Kang YS, Han SY, et al. Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 2008;23:2750-2760.
31. Toblli JE, Ferrini MG, Cao G, et al. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transplant 2009;24:2384-2391.
32. Pistrosch F, Herbrig K, Kindel B, et al. Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetes nephropaty in patientes. Diabetes 2005;54:2206-2211. (Pubitemid 40911285)
33. Bozkurt D, Taskin H, Sezak M, et al. Rosiglitazone, a peroxisome proliferator-activated receptor agonist, improves peritoneal alterations resulting from an encapsulated peritoneal sclerosis model. Adv Perit Dial 2008;24:32-38.
34. Yao Q, Pawlaczyk K, Ayala ER, et al. Peroxisome proliferator-activated receptor-gamma agonists diminish peritoneal functional and morphological changes induced by bioincompatible peritoneal dialysis solution. Blood Purif 2006;24:575-582. (Pubitemid 46030101)
35. González-Mateo GT, Loureiro J, Jiménez-Hefferman JA, et al. Chronic exposure of mouse peritoneum to peritoneal dialysis fluid: structural and functional alterations of the peritoneal membrane. Perit Dial Int 2009;29:227-230.
36. Catalan MP, Reyero A, Egido J, et al. Acceleration of neutrophil apoptosis by glucose-containing peritoneal dialysis solutions: role of caspases. J Am Soc Nephrol 2001;12:2442-2449. (Pubitemid 33021122)
37. Justo P, Lorz C, Sanz A, et al. Intracellular mechanisms of cyclosporin A-induced tubular cell apoptosis. J Am Soc Nephrol 2003;14: 3072-3080. (Pubitemid 37509285)
38. Na HK, Surh YJ. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) ligands as bifunctional regulator of cell proliferation. Biochem Pharmacol 2003;66:1381-1391. (Pubitemid 38373324)
39. Ren Y, Sun C, Sun Y, et al. PPAR gamma protects cardiomyocytes against oxidative stress and apoptosis via Bcl-2 upregulation. Vascul Pharmacol 2009;51:169-174.
40. Wu JS, Lin TN, Wu KK. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J Cell Physiol 2009;220:58-71.
41. Kwon CH, Park JY, Kim TH, et al. Ciglitazone induces apoptosis via activation of p38 MAPK and AIF nuclear translocation mediated by reactive oxygen species and Ca(2+) in opossum kidney cells. Toxicology 2009;257:1-9.
42. Sun WH, Chen GS, Ou XL, et al. Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 2009;275:247-255.
43. Kwon CH, Yoon CS, Kim YK. Ciglitazone induces caspase-independent apoptosis via p38-dependent AIF nuclear translocation in renal epithelial cells. Toxicology 2008;244:13-24.
44. Strippoli R, Benedicto I, Pérez Lozano ML, et al. Epithelial-tomesenchymal transition of peritoneal mesothelial cells is regulated by an ERK/NF-kappaB/Snail1 pathway. Dis Model Mech 2008;1: 264-274.
45. Yao Q, Ayala ER, Qian JQ, et al. A combination of a PPAR-gamma agonist and an angiotensin II receptor blocker attenuates proinflammatory signaling and stimulates expression of Smad7 in human peritoneal mesothelial cells. Clin Nephrol 2007;68:295-301. (Pubitemid 350047762)
46. De Vriese AS, Tilton RG, Mortier S, et al. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006;21:2549-2555. (Pubitemid 44644530)
47. Schwenger V, Morath C, Salava A, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006;17:199-207.
48. Boulanger E, Wautier MP, Wautier JL, et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002;61:148-156. (Pubitemid 34075141)
49. Boulanger E, Grossin N, Wautier MP, et al. Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. Kidney Int 2007;71:126-133. (Pubitemid 46094685)
50. Hirahara I, Ishibashi Y, Kaname S, et al. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant 2009;24:437-447.
51. Conti G, Amore A, Cirina P, et al. Glycated adducts induce mesothelial cell transdifferentiation: role of glucose and icodextrin dialysis solutions. J Nephrol 2008;21:426-437.
52. Nevado J, Peirö C, Vallejo S, et al. Amadori adducts activate nuclear factor-kappaB-related proinflammatory genes in cultured human peritoneal mesothelial cells. Br J Pharmacol 2005;146:268-279. (Pubitemid 43079967)
53. Boulanger E, Wautier MP, Gane P, et al. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products. Nephrol Dial Transplant 2004;19:2208-2216. (Pubitemid 39214112)
54. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-1554. (Pubitemid 40923063)
55. Axelsson J, Carrero JJ, Avesani CM, et al. Adipokine signaling in the peritoneal dialysis patient. Contrib Nephrol 2006;150:166-173. (Pubitemid 44155347)
56. Leung JC, Chan LY, Tang SC, et al. Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int 2006;69:2078-2086.
57. Yang AH, Huang SW, Chen JY, et al. Leptin augments myofibroblastic conversion and fibrogenic activity of human peritoneal mesothelial cells: a functional implication for peritoneal fibrosis. Nephrol Dial Transplant 2007;22:756-762.
58. Maynard CL, Weaver CT. Diversity in the contribution of IL-10 to T-cellmediated immune regulation. Immunol Rev 2008;226:219-233.
59. Kapp JA, Honjo K, Kapp LM, et al. TCR transgenic CD8+ T cells activated in the presence of TGFbeta express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection. Int Immunol 2006;18:1549-1562. (Pubitemid 44605576)
60. Rizos CV, Elisaf MS, Mikhailidis DP, et al. How safe is the use of thiazolidinediones in clinical practice? Expert Opin Drug Saf 2009; 8:15-32.
61. Aramwit P, Supasyndh O, Sriboonruang T. Pharmacokinetics of singledose rosiglitazone in chronic ambulatory peritoneal dialysis patients. J Clin Pharm Ther 2008;33:685-690.
62. Iglesias P, Díez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 2006;154:613-621. (Pubitemid 43810845)